Ewing Sarcoma – Pipeline Review, H2 2017 – iCrowdNewswire
 
x

RSS Newsfeeds

See all RSS Newsfeeds

Dec 7, 2017 1:40 PM ET

Ewing Sarcoma – Pipeline Review, H2 2017

iCrowdNewswire - Dec 7, 2017

The “Ewing Sarcoma – Pipeline Review, H2 2017” report has been added to Research and Markets’ offering.

Ewing Sarcoma – Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Ewing Sarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ewing Sarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Ewing Sarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 13, 6, 20 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 2, 2 and 2 molecules, respectively.

Ewing Sarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

– Introduction
– Ewing Sarcoma – Overview
– Ewing Sarcoma – Therapeutics Development
– Pipeline Overview
– Pipeline by Companies
– Pipeline by Universities/Institutes
– Products under Development by Companies
– Products under Development by Universities/Institutes
– Ewing Sarcoma – Therapeutics Assessment
– Assessment by Target
– Assessment by Mechanism of Action
– Assessment by Route of Administration
– Assessment by Molecule Type
– Ewing Sarcoma – Companies Involved in Therapeutics Development

– Amgen Inc
– AntiCancer Inc
– Astellas Pharma Inc
– Bristol-Myers Squibb Co
– Cebiotex SL
– Celgene Corp
– Celldex Therapeutics Inc
– Eisai Co Ltd
– EntreChem SL
– Exelixis Inc
– Gradalis Inc
– Incyte Corp
– Ipsen SA
– MacroGenics Inc
– MediaPharma SRL
– Merck & Co Inc
– Merrimack Pharmaceuticals Inc
– NantKwest Inc
– Novartis AG
– Oncomatryx Biopharma SL
– Oncternal Therapeutics Inc
– Pfizer Inc
– Pharma Mar SA
– Tarveda Therapeutics Inc
– Tesaro Inc

For more information about this report visit https://www.researchandmarkets.com/research/blxs58/ewing_sarcoma?w=3

Contact Information:

Research and Markets,
Laura Wood,
Senior Manager.
[email protected]
Related Topics: Oncology Drugs (https://www.researchandmarkets.com/categories.asp?cat_id=122&campaign_id=blxs58)

Via iCrowdNewswire
View Related News >